基于IL-33/ST2-ILC2轴探讨鼻敏康合剂治疗变应性鼻炎MPI的分子机制

易于复发是变应性鼻炎（AR）治疗的难点，AR在缓解期鼻黏膜仍存在持续性炎症反应(MPI)，是其复发的关键，调控MPI局部炎症是减少AR复发的根本。前期根据《内经》理论提出“阳气失于和利”是AR发病和MPI炎症持续的关键，在“和利阳气法”指导下研发的鼻敏康合剂可调控ILCs的平衡治疗AR。最新研究表明，ILC2是MPI关键的细胞免疫基础，在IL-33/ST2的作用下激活并聚集，主导了AR及MPI鼻黏膜的免疫性炎症反应。因此，本课题采用细胞培养、RT-qPCR和Western Blot等技术观察鼻敏康合剂对MPI靶器官鼻腔黏膜IL-33/ST2-ILC2轴关键蛋白及基因（IL-33、ST2、NF-κBp65、p38、JNK、ERK）表达的影响，阐明变应性鼻炎MPI“阳气失于和利”的免疫学机制，探讨鼻敏康合剂调控MPI防止AR复发的机制，为中药防治AR提供科学依据。

The high recurrence rate is a difficult problem in the treatment of AR.The minimum persistent inflammatory(MPI) still exists in the nasal mucosa of patients with allergic rhinitis (AR) in remission stage,which is the key to AR recurrence.Regulation of local inflammation in MPI is the fundamental to reduce AR recurrence.According to the theory of Neijing, it was previously proposed that Yang Qi deficiency is the key factor for the occurrence of AR and the continuation of MPI inflammation. Under the guidance of "Heli Yangqi theory",Bimin Kang Mixture developed can treat AR by regulating the transformation of ILCs subsets.Recent studies have shown that ILC2 is the key cellular immune basis of MPI stage, which is activated and aggregated under the action of IL-33/ST2,and plays a leading role in the immunological inflammatory response of AR and MPI nasal mucosa. Therefore, cell culture,RT qPCR and Western Blot were used in this study objective to observe the effect of Bimin Kang Mixture on the expression of IL-33/ST2-ILC2 axis key proteins and genes (IL-33、ST2、NF-κBp65、p38、JNK、ERK) in nasal mucosa of target organ in MPI stage,and to elucidate the immunological mechanism of Yang Qi deficiency in MPI stage of allergic rhinitis,and to explore the mechanism of Biminkang mixture regulating MPI to prevent ar recurrence, so as to provide scientific basis for the prevention and reatment of AR with traditional Chinese medicine.